Deals and Financings Jiangsu Hengrui Pharma out-licensed global rights (ex-China) for its next-gen PARP1 inhibitor to Germany’s Merck KGaA (OTCPK:MKGAF) for a $170 million
TransUnion (NYSE:) CIBIL’s Credit Market Indicator (CMI) for Q2 2023 has revealed a rise in balance-level serious delinquencies across all product categories, with the